JP2008543748A - ピラゾロピリミジノン誘導体を含む肝疾患の予防及び治療剤 - Google Patents
ピラゾロピリミジノン誘導体を含む肝疾患の予防及び治療剤 Download PDFInfo
- Publication number
- JP2008543748A JP2008543748A JP2008515614A JP2008515614A JP2008543748A JP 2008543748 A JP2008543748 A JP 2008543748A JP 2008515614 A JP2008515614 A JP 2008515614A JP 2008515614 A JP2008515614 A JP 2008515614A JP 2008543748 A JP2008543748 A JP 2008543748A
- Authority
- JP
- Japan
- Prior art keywords
- liver
- portal
- present
- portal hypertension
- portal vein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
1)本発明は、肝線維化抑制剤を提供する。2)また、本発明は肝線維化を抑制する肝硬変予防及び治療用医薬組成物を提供する。3)さらに、本発明は門脈圧亢進抑制剤を提供する。4)また、門脈圧亢進により誘発される合併症の予防及び治療用医薬組成物を提供する。
本発明のピラゾロピリミジノン誘導体のコラーゲン合成抑制効果を調べるために、下記の実験を遂行した。
本発明のピラゾロピリミジノン誘導体のコラーゲン合成抑制効果を生体内実験を通じて調べるために、下記の実験を行った。
本発明のピラゾロピリミジノン誘導体の門脈圧亢進に対する効果を調べるために、下記の実験を行った。
門脈圧亢進症患者の中で19歳から45歳の間の年齢に属する志願者を対象にして、体重が45kg以上で理想体重(ideal body weight)の15%偏差以内にあり、自らの考えで参加を決めて書面同意し、試験者を信頼し、協力的であり、制限事項を順守する人を選定した。選定した患者を無作為に3群に分け、ピラゾロピリミジノン誘導体、シルデナフィル及びバルデナフィルをそれぞれ100、50及び10mgの用量で服用するようにした。参加者は9人で、そのうち3人はピラゾロピリミジノン誘導体、他の3人はシルデナフィル、残りの3人にはバルデナフィルを服用するようにした。
1.散剤の製造
ピラゾロピリミジノン誘導体 2g
乳糖 1g
前記の成分を混合し、気密袋に充填して散剤を製造した。
ピラゾロピリミジノン誘導体 100mg
トウモロコシデンプン 100mg
乳糖 100mg
ステアリン酸マグネシウム 2mg
前記の成分を混合した後、通常の錠剤の製造方法にしたがって打錠し、錠剤を製造した。
ピラゾロピリミジノン誘導体 100mg
トウモロコシデンプン 100mg
乳糖 100mg
ステアリン酸マグネシウム 2mg
前記の成分を混合した後、通常のカプセル剤の製造方法にしたがってゼラチンカプセルに充填し、カプセル剤を製造した。
Claims (5)
- 下記の化学式1で表されるピラゾロピリミジノン誘導体を有効成分として含む肝線維化抑制剤。
- 下記の化学式1で表されるピラゾロピリミジノン誘導体を有効成分として含む、肝硬変予防及び治療用医薬組成物。
- 下記の化学式1で表されるピラゾロピリミジノン誘導体を有効成分として含む門脈圧亢進抑制剤。
- 下記の化学式1で表されるピラゾロピリミジノン誘導体を有効成分として含む、門脈圧亢進症から誘発される合併症の予防及び治療用医薬組成物。
- 門脈圧亢進症から誘発される合併症が、食道静脈瘤、脾臓腫大及び脾機能亢進症、腹水症、特発性細菌性腹膜炎、肝腎症候群、肝性脳症または肝肺症候群からなる群から選択されるいずれか1つ以上であることを特徴とする、請求項4に記載の門脈圧亢進症から誘発される合併症の予防及び治療用医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2005-0050033 | 2005-06-10 | ||
KR20050050033 | 2005-06-10 | ||
PCT/KR2005/003526 WO2006132460A1 (en) | 2005-06-10 | 2005-10-21 | Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008543748A true JP2008543748A (ja) | 2008-12-04 |
JP4879977B2 JP4879977B2 (ja) | 2012-02-22 |
Family
ID=37498629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008515614A Expired - Fee Related JP4879977B2 (ja) | 2005-06-10 | 2005-10-21 | ピラゾロピリミジノン誘導体を含む肝疾患の予防及び治療剤 |
Country Status (22)
Country | Link |
---|---|
US (1) | US8796286B2 (ja) |
EP (1) | EP1888074B1 (ja) |
JP (1) | JP4879977B2 (ja) |
KR (1) | KR100914445B1 (ja) |
CN (1) | CN101193636B (ja) |
AT (1) | ATE537832T1 (ja) |
AU (1) | AU2005332719B2 (ja) |
BR (1) | BRPI0520209A2 (ja) |
CA (1) | CA2611638C (ja) |
CY (1) | CY1112637T1 (ja) |
DK (1) | DK1888074T3 (ja) |
ES (1) | ES2376628T3 (ja) |
HK (1) | HK1119596A1 (ja) |
IL (1) | IL187678A (ja) |
MX (1) | MX2007015365A (ja) |
NO (1) | NO20076053L (ja) |
NZ (1) | NZ564369A (ja) |
PT (1) | PT1888074E (ja) |
RU (1) | RU2369392C2 (ja) |
UA (1) | UA86528C2 (ja) |
WO (1) | WO2006132460A1 (ja) |
ZA (1) | ZA200800180B (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013532635A (ja) * | 2010-07-14 | 2013-08-19 | カンバーランド エマージング テクノロジーズ,インコーポレーテッド | トロンボキサン−a2受容体アンタゴニストでの肝腎症候群および肝性脳症の治療方法 |
JP2015525637A (ja) * | 2012-07-11 | 2015-09-07 | ユニバーシティー オブ ミシシッピ メディカル センター | 画像獲得データから肝線維症を検出及びステージ決定する方法 |
US9693998B2 (en) | 2014-05-16 | 2017-07-04 | Cumberland Pharmaceuticals, Inc. | Compositions and methods of treating cardiac fibrosis with ifetroban |
US11571412B2 (en) | 2015-06-30 | 2023-02-07 | Cumberland Pharmaceuticals Inc. | Thromboxane receptor antagonists in AERD/asthma |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100322917A1 (en) * | 2006-12-28 | 2010-12-23 | Insect Biotech Co., Ltd. | Pharmaceutical composition containing arazyme for the prevention of liver dysfunction |
WO2010118367A2 (en) * | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
AU2017263462B2 (en) | 2016-05-11 | 2021-05-13 | Cumberland Pharmaceuticals, Inc. | Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonists |
CN110833556A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药(集团)股份有限公司 | 吡唑并嘧啶衍生物在治疗肝纤维化的用途 |
CN113493459B (zh) * | 2020-04-07 | 2022-12-13 | 广州白云山医药集团股份有限公司白云山制药总厂 | Pde5抑制剂化合物及其制备方法和应用 |
CA3229274A1 (en) * | 2021-08-13 | 2023-02-16 | Mezzion Pharma Co., Ltd. | Methods and compositions for treating fibrotic liver conditions, using udenafil compositions |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000027848A1 (en) * | 1998-11-11 | 2000-05-18 | Dong A Pharm. Co., Ltd. | Pyrazolopyrimidinone derivatives for the treatment of impotence |
WO2003063875A1 (en) * | 2002-01-31 | 2003-08-07 | Pfizer Limited | Use of pde5 inhibitors in the treatment of scarring and fibrosis |
WO2004002461A2 (en) * | 2002-06-26 | 2004-01-08 | Pfizer Limited | Combination of pde5 inhibitors with angiotensin ii receptor antagonists |
WO2004108062A2 (de) * | 2003-06-06 | 2004-12-16 | Universitätsklinikum Freiburg | Prophylaxe und/oder therapie bei der portalen hypertonie |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100377782B1 (ko) | 2000-06-23 | 2003-03-29 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법 |
US20030216407A1 (en) * | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
EP1336602A1 (en) | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
WO2004037183A2 (en) | 2002-10-22 | 2004-05-06 | Harbor-Ucla Research And Education Institute | Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases |
JPWO2004108662A1 (ja) | 2003-05-15 | 2006-07-20 | クミアイ化学工業株式会社 | フェニルスルホニルカーバメイト誘導体及び農園芸用植物病害防除剤 |
JP2006527257A (ja) | 2003-06-10 | 2006-11-30 | ファイザー・インク | 月経困難症の治療用のpde阻害剤及びバソプレッシン受容体アンタゴニストを含んでなる療法組合せ |
DE102005001989A1 (de) | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
-
2005
- 2005-10-21 DK DK05808627.3T patent/DK1888074T3/da active
- 2005-10-21 RU RU2007149474/15A patent/RU2369392C2/ru active
- 2005-10-21 AU AU2005332719A patent/AU2005332719B2/en not_active Ceased
- 2005-10-21 UA UAA200713931A patent/UA86528C2/uk unknown
- 2005-10-21 ES ES05808627T patent/ES2376628T3/es active Active
- 2005-10-21 WO PCT/KR2005/003526 patent/WO2006132460A1/en active Application Filing
- 2005-10-21 KR KR1020050099900A patent/KR100914445B1/ko active IP Right Grant
- 2005-10-21 AT AT05808627T patent/ATE537832T1/de active
- 2005-10-21 US US11/916,752 patent/US8796286B2/en active Active
- 2005-10-21 PT PT05808627T patent/PT1888074E/pt unknown
- 2005-10-21 EP EP05808627A patent/EP1888074B1/en active Active
- 2005-10-21 CN CN2005800500656A patent/CN101193636B/zh not_active Expired - Fee Related
- 2005-10-21 BR BRPI0520209-4A patent/BRPI0520209A2/pt not_active IP Right Cessation
- 2005-10-21 NZ NZ564369A patent/NZ564369A/en not_active IP Right Cessation
- 2005-10-21 MX MX2007015365A patent/MX2007015365A/es active IP Right Grant
- 2005-10-21 CA CA2611638A patent/CA2611638C/en not_active Expired - Fee Related
- 2005-10-21 JP JP2008515614A patent/JP4879977B2/ja not_active Expired - Fee Related
-
2007
- 2007-11-26 NO NO20076053A patent/NO20076053L/no not_active Application Discontinuation
- 2007-11-27 IL IL187678A patent/IL187678A/en not_active IP Right Cessation
-
2008
- 2008-01-08 ZA ZA200800180A patent/ZA200800180B/xx unknown
- 2008-11-27 HK HK08112976.5A patent/HK1119596A1/xx not_active IP Right Cessation
-
2012
- 2012-03-14 CY CY20121100272T patent/CY1112637T1/el unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000027848A1 (en) * | 1998-11-11 | 2000-05-18 | Dong A Pharm. Co., Ltd. | Pyrazolopyrimidinone derivatives for the treatment of impotence |
WO2003063875A1 (en) * | 2002-01-31 | 2003-08-07 | Pfizer Limited | Use of pde5 inhibitors in the treatment of scarring and fibrosis |
WO2004002461A2 (en) * | 2002-06-26 | 2004-01-08 | Pfizer Limited | Combination of pde5 inhibitors with angiotensin ii receptor antagonists |
WO2004108062A2 (de) * | 2003-06-06 | 2004-12-16 | Universitätsklinikum Freiburg | Prophylaxe und/oder therapie bei der portalen hypertonie |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013532635A (ja) * | 2010-07-14 | 2013-08-19 | カンバーランド エマージング テクノロジーズ,インコーポレーテッド | トロンボキサン−a2受容体アンタゴニストでの肝腎症候群および肝性脳症の治療方法 |
JP2015525637A (ja) * | 2012-07-11 | 2015-09-07 | ユニバーシティー オブ ミシシッピ メディカル センター | 画像獲得データから肝線維症を検出及びステージ決定する方法 |
US10130295B2 (en) | 2012-07-11 | 2018-11-20 | University Of Mississippi Medical Center | Method for the detection and staging of liver fibrosis from image acquired data |
US9693998B2 (en) | 2014-05-16 | 2017-07-04 | Cumberland Pharmaceuticals, Inc. | Compositions and methods of treating cardiac fibrosis with ifetroban |
US10016399B2 (en) | 2014-05-16 | 2018-07-10 | Cumberland Pharmaceuticals Inc. | Compositions and methods of treating cardiac fibrosis with ifetroban |
US11571412B2 (en) | 2015-06-30 | 2023-02-07 | Cumberland Pharmaceuticals Inc. | Thromboxane receptor antagonists in AERD/asthma |
Also Published As
Publication number | Publication date |
---|---|
HK1119596A1 (en) | 2009-03-13 |
ES2376628T3 (es) | 2012-03-15 |
AU2005332719A1 (en) | 2006-12-14 |
WO2006132460A1 (en) | 2006-12-14 |
CY1112637T1 (el) | 2016-02-10 |
AU2005332719B2 (en) | 2010-05-13 |
US20080207646A1 (en) | 2008-08-28 |
CA2611638C (en) | 2010-08-24 |
JP4879977B2 (ja) | 2012-02-22 |
PT1888074E (pt) | 2012-03-01 |
RU2369392C2 (ru) | 2009-10-10 |
BRPI0520209A2 (pt) | 2009-04-22 |
NO20076053L (no) | 2008-02-27 |
US8796286B2 (en) | 2014-08-05 |
CN101193636B (zh) | 2011-12-28 |
EP1888074B1 (en) | 2011-12-21 |
DK1888074T3 (da) | 2012-01-23 |
IL187678A (en) | 2013-04-30 |
NZ564369A (en) | 2010-03-26 |
EP1888074A1 (en) | 2008-02-20 |
ATE537832T1 (de) | 2012-01-15 |
EP1888074A4 (en) | 2010-06-23 |
ZA200800180B (en) | 2009-01-28 |
IL187678A0 (en) | 2008-11-03 |
RU2007149474A (ru) | 2009-07-20 |
CN101193636A (zh) | 2008-06-04 |
MX2007015365A (es) | 2008-02-12 |
CA2611638A1 (en) | 2006-12-14 |
KR20060128605A (ko) | 2006-12-14 |
KR100914445B1 (ko) | 2009-08-28 |
UA86528C2 (uk) | 2009-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4879977B2 (ja) | ピラゾロピリミジノン誘導体を含む肝疾患の予防及び治療剤 | |
JP6557684B2 (ja) | 線維性疾患の治療に用いられるppar化合物 | |
TW201119651A (en) | Pharmaceutical composition comprising indole compound | |
CA2767331A1 (en) | Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity | |
EP3288555A1 (en) | Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof | |
TWI564291B (zh) | 一氧化氮生成調節劑 | |
HUE030700T2 (en) | Hepatocyte growth factor (scatter factor) modulator pyrazole derivatives | |
JP2022062115A (ja) | sGC刺激剤のリンプロドラッグ | |
WO2001013916A1 (fr) | Medicaments inhibant la mort cellulaire | |
JP2002517443A (ja) | Hivプロテアーゼ阻害剤の浸透を増加させる方法および組成物 | |
EP2397129A1 (en) | Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis | |
CA2813719A1 (en) | Methods of use of small molecule modulators of hepatocyte growth factor (scatter factor) activity | |
KR101891360B1 (ko) | 간세포암의 예방 및/또는 치료를 위한 의약 | |
AU2016212555A1 (en) | Sunitinib prodrug and pharmaceutical composition | |
Li et al. | Injectable, Drug-Eluting Nanocrystals Prevent Fibrosis and Stricture Formation In Vivo | |
JPH0834734A (ja) | 平滑筋細胞増殖に起因する疾患の治療・予防剤 | |
KR101741046B1 (ko) | 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 신규 피페라진 유도체 및 이의 의학적 용도 | |
KR100860326B1 (ko) | 에포틸론 b를 함유하는 혈관재협착 예방 및 치료제 | |
IL305037A (en) | Methods of treating glioblastomas with spiafatrin | |
OA19197A (en) | Pharmaceutical composition for use in the theurapeutic treatment of cancer and complications of cancer. | |
CN117447480A (zh) | E20在化疗致卵巢损伤保护中的应用 | |
JPH03287534A (ja) | 肝疾患治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110531 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110831 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110907 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110930 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111122 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111130 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141209 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |